Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

• Status: Recruiting
• Trial end date: 2026-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peng Zhang
• Treatments: Abrocitinib; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Tofacitinib

Criteria

Inclusion Criteria:

1. Age 18 and above.

2. Diagnosed with SJS/TEN according to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria.

3. Liver and kidney function is within acceptable ranges.

4. Blood parameters, including complete blood count, coagulation function, and platelet count, are within acceptable ranges.

5. Patients must sign an informed consent form, understanding the risks and potential benefits of the treatment.

6. Patients need to be capable of participating in follow-up visits and treatment plans.

Exclusion Criteria:

1. History of allergy to JAK inhibitors.

2. Pregnant or breastfeeding women.

3. Severe infectious conditions.

4. History of central nervous system demyelinating diseases.

5. History of lymphoproliferative diseases.

6. Active and latent tuberculosis.

7. HIV carriers with a CD4+ T cell count lower than (<200/mL).

8. Active HBV/HCV infection.

9. Coagulation disorders or a tendency for thrombosis.

10. Significant abnormalities in blood routine indicators.

11. Liver or kidney dysfunction.